Home/Pipeline/ANAVEX®3-71

ANAVEX®3-71

Schizophrenia

Phase 2OngoingSZ-001

Key Facts

Indication

Schizophrenia

Phase

Phase 2

Status

Ongoing

Company

Anavex Life Sciences

About Anavex Life Sciences

Anavex Life Sciences is a clinical-stage biotech focused on developing oral therapeutics for central nervous system (CNS) disorders by targeting the sigma-1 receptor (SIGMAR1). Its lead asset, blarcamesine, has generated pivotal clinical data in Alzheimer's disease and holds Orphan Drug Designation for Rett syndrome, positioning it in multi-billion dollar markets with high unmet need. The company operates with a lean, virtual model, advancing a precision medicine platform that aims to modify disease pathology rather than just alleviate symptoms.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Neurodevelopmental Disorders

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Olanzapine LAI (TEV-‘749)	Teva	Phase 3	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active
Risperidone Implant	Delpor	Phase 1b/2a / Late-stage	Active
Preclinical Kv3 Modulators	Autifony Therapeutics	Preclinical	Active